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Abstract 
Particular cognitive deficits such as attentional biases toward drug related stimuli 
(driven by low-level ‘bottom-up’ processes) and problems with inhibiting actions 
(executive or ‘top-down’ processes), appear to be associated with substance use 
disorder. Study used two experiments (One: 7 participants with mean age of 41.7 years, 
two: 67 participants with mean age 34.3 years) to test the theoretical framework 
proposed by Manning et. al. (2017). Poorer ‘top-down’ inhibitory cognition and 
greater ‘bottom-up’ drives: (according to the model) should be related to severity of 
substance use disorder (predicted by the model) correlate with poorer treatment 
outcomes (early drop out; tested at week 4 and 12). The study findings showed mixed 
evidence to support the theory underpinning the framework with significant bottom-
up compulsivity measure but not top-down response inhibition. The predictions made 
by the framework were not supported. Previous studies analyzing the relation between 
cognition and treatment outcomes failed to control for psychological distress and 
readiness to change. After controlling for other key correlates of treatment dropout 
(anxiety, and readiness to change), top-down (SST) measure was significantly 
associated with treatment outcomes. The findings highlight the multifaceted way in 
which people can remain stuck in substance use disorder.  
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Substance use disorder (SUD) is one of society’s most prevalent health and 
social problems (AIHW, 2017). Globally, 0.6% per cent of the adult population 
suffer from SUD (UNODC, 2017). In 2015, SUD was the fifth leading disorder 
category with an estimated 17 million years of "healthy" life (disability-adjusted life 
years) lost as a result of premature death and disability (UNODC, 2017).  SUD has a 
significant impact on all aspects of an individual’s wellbeing (NIDA, 2009) as well 
as a larger social and economic burden (UNODC, 2017). Collins and Lapsley (2008) 
found the total costs of drug use within Australia during 2004/2005 exceeded A$55 
billion, with alcohol costing A$15.3 billion, and illicit drugs A$8.2 billion.   
A substantial amount of recent psychological research has been conducted in 
attempts to better understand outpatient treatment outcomes for those presenting with 
substance use disorder. In 2016–17, around 193,031 clients engaged in government-
funded alcohol and drug treatment in Australia (AIHW, 2017). Figure 1 shows the 
trend patterns for treatment provided by drug type over the last 10 years. Overall the 
number of treatment episodes provided has increased by 24% over the 10-year period 
(AIHW, 2017).   
 
Figure 1. Closed treatment episodes for own drug use, by the four main principal drugs of concern, 
2007–08 to 2016–17 (AIHW,2017).  
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Definition and Symptomatic criteria for SUD in the DSM-5 
	
SUD is characterized in the DSM-5 as significant distress (social, 
psychological and physical) as a result of as a result of continued drug-taking 
behaviour (American Psychiatric Association, 2013). Individual substances are 
addressed as use-specific disorders (i.e. alcohol-use disorder, cannabis-use disorder 
act.), however, they are all diagnosed according to the same diagnostic criteria 
(Hasin et. al., 2013). This is because the mechanisms underlying the chronic and 
chronic effects of drugs are the same. Chronic substance use alters the physical 
structure of the brain by hijacking the ventral tegmental area and mesolimbic 
pathway, altering its function after the repeated dopaminergic surge by increasing the 
dopaminergic neurons when substances are repeatedly drug is administered 
(Lubman, Yucel & Pantelis, 2004). This, redirecting the individual to seek the 
addictive substance instead of healthy pleasure seeking (food, sex etc., Dennis & 
Scott, 2007). Despite negative consequences, people with SUD continue to use these 
substances (Lubman et al., 2004). These drug-seeking and drug-taking behavioral 
patterns are consistent across drug type and are exacerbated in chronic users (Elman 
& Borsook, 2016).  
There are 11 symptomatic criteria for SUD in the DSM-5 (American 
Psychiatric Association, 2013; see table 1). Severity of SUD is measured by criteria 
count; mild (two to three criteria), moderate (four to five), and severe (six or more; 
American Psychiatric Association, 2013). 
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Table 1  
Symptomatic criteria for SUD in the DSM-5 (American Psychiatric Association, 
2013). 
Criteria Grouping Criteria N 
Impaired Control Drug use in larger amounts or over a longer period of time 
than intended 
1 
Persistent desire to cut down and problems doing so 2 
Time spent obtaining or recovering from drug effects 
increases 
3 
Craving or strong desire to use 4 
Social Impairment Recurrent drug use resulting in failure to fulfill major role 
obligations at work, school, or home 
5 
Recurrent drug use resulting in recurrent social or 
interpersonal problems 
6 
Given up or reduced important social occupational or 
recreational activities because of use 
7 
Risky Use Recurrent drug use in physically hazardous situations  8 
Continued use despite knowledge of physical OR mental 
problem exacerbated by drug 
9 
Physiological adaptation Tolerance 10 
Withdrawal  11 
 
Psychosocial Treatment 
	
Engagement in treatment programs is necessary for successful treatment 
outcomes. As SUD is multifaceted disorder and impacts many aspects of a person’s 
wellbeing, psychosocial treatment is tailored to the individual rather than the 
substance used (NIDA, 2009). Psychosocial, ‘talk-based therapy’ is a common 
treatment and front-line intervention for problems with cannabis, alcohol and 
amphetamine use (AIHW, 2017). Common interventions include cognitive behavior 
therapy (CBT), goal setting, relapse prevention tenancies, motivational enhancement 
therapy (MET), psychodynamic therapy/interpersonal therapy, case management, 
and group, marital, and family therapies (Kilmas et. al., 2014).   
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The current state of the literature suggests that psychosocial interventions are 
the most effective treatments for cannabis (Gates, et. al., 2017) and 
methamphetamine (Perez-Mana, et.al., 2013) use disorder, and are effective 
interventions for alcohol use disorder when paired with with pharmacological 
treatment options (Kilmas et. al., 2014). 
Prominence of Treatment Drop-out and Relapse 
	
In 2016–17 overall, clients seeking treatment for their own drug use received 
an average of 1.6 treatment episodes (AIHW,2017). The overall average in Tasmania 
being 1.4 treatment episodes (AIHW, 2017). To see symptom improvement through 
treatment engagement, a minimum of three months is recommended with symptom 
improvement increasing linearly with length of treatment engagement (Katz, et. al. 
2004). Studies show consistent treatment engagement contribute to greater rates of 
abstinence (Winters, Fawkes, Fahnhorst, Botzet, & August, 2007). Cannabis using 
populations showed greater treatment outcome to be associated with consistent 
psychosocial treatment (Gates, et. al., 2017).  
 
However, dropout rates for those engaged in outpatient ‘talk-based’ therapy 
were alarmingly high with more than half (55%) engaged in therapy for less than a 
month (AIHW, 2017). Dropout after three months increased by 24%, while after 
twelve months were over 75% (AIHW, 2017). Dropout rates have shown to be 
consistent across drug type (Sofuglu, DeVito, Waters, & Carroll, 2013), with similar 
trends internationally. In the United States, drop-out rates within the first month are 
approximately 30% and approximately 50% within the first 3 months (Palmer, 
Murphy, Piselli, & Ball, 2013; Loveland & Driscoll, 2014). Similar rates (23-50% 
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drop-outs in 8 weeks) have been observed in Europe (Simsek, Dinc, Ogel, 2018), 
South America (57% in first month; Passor & Camacho, 2000) and India (61.3% in 
first month; Basu et. al, 2017).  
 
Treatment approaches historically have adopted a disease based framework 
with abstinence being the main goal (Worley et.al., 2012). However, it is not 
uncommon for relapse to occur many times in the process of recovery (Worley et.al., 
2012). Clinicians therefore lean towards a harm reduction approach with use 
reduction being the immediate goal and abstinence the long term goal (Worley et.al., 
2012). Relapse, following a period of abstinence, is a logical consequence of a 
behavioural conditioning process, as drug seeking-habits are reactivated by drug-
cues (Robbins & Everitt, 1999). Triggering events can be classed into three main 
categories, the administration of a similar drug, the presence of a drug-conditioned 
stimulus and/or the induction of a state of stress (Robbins & Everitt, 1999). 
Prevalence of Cognitive Impairment in SUD populations 
	
Studies have consistently found impairments in cognitive functioning, such as 
executive memory, decision making, attention and response inhibition to be factors 
contributing to therapy engagement (Manning, Verdejo-Garcia & Lubman, 2017). 
Illicit substances all produce some impairment in neuropsychological mechanisms, 
as well as additional substance-specific impairments (Fernandez-Serrano, Perez-
Garcia, & Verdejo-Garcia, 2011). Prolonged substance use causes change in the 
structure and synaptic connections in the brain (Volkow & Li, 2004). These 
impairments are exacerbated in those with more servere SUD (Volkow, Fowler, & 
Wang, 2003).   
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A systematic review conducted by Fernandez-Serrano, Perez-Garcia, and 
Verdejo-Garcia, (2011) found both substance-specific and generalized substance use 
disorder-related cognitive deficits. This systematic review used peer-reviewed 
studies from the PubMed and PsycInfo databases, investigated both specific and 
generalized cognitive impairments and differentiates between pure and poly-
substance studies. Results from mono substance users of particular interest with 
results reported in Table 2. 
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Table 2 
Cognitive impairment effect sizes in mono substance users adapted from Fernandez-Serrano, Perez-Garcia, & Verdejo-Garcia, 2011 
Cognitive 
impairments 
Cannabis Cocaine Methamphetamines MDMA Heroin Alcohol 
 n d n d n d n d n d n d 
Episodic memory 1 2.31   1 0.87 2 1.04 1 0.48 3 0.35 
Semantic memory 1 3.00     2 0.50     
Selective attention *       1 1.40   2 0.83 
Sustained attention        1 0.51   1 1.03 
Updating fluency       2 0.63   1 0.05 
Updating reasoning 1 0.39       1 0.71 1 0.10 
Updating working 
memory 
      2 0.40 1 0.53 2 0.28 
Psychomotor 
functioning 
      2 0.96   2 0.74 
Spatial processing 1 1.20     1 0.58   1 0.84 
Cognitive flexibility*        1 0.35   3 0.45 
Impulsive actions*     1 0.82 1 0.54 1 0.27 3 0.49 
Impulsive choice*           1 0.17 
Decision making*   2 0.63   1 0.27 1 3.8 2 0.26 
Note: n = number of studies used to calculate the mean effect size. d = mean effect sizes (Cohenˇıs d). bold: Mean effect sizes reaching at least a moderate magnitude (mean 
Cohenˇıs d ≥ 0.5) across studies. * = Impairments of interested to this study. Mean effect sizes were reported regardless of the statistical significance (p-value) of the results 
reported in original studies.. Blank cells relate to conditions where no data was available for meta-analysis. 
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While there are a number of other deficits, of particular relevance to the 
current study are impairments with executive control, which are common across 
substance type. Deficits in selective attention were found in MDMA and alcohol 
studies with effect sizes of moderate magnitude. Two studies assessing cannabis and 
heroin polysubstance found impairments in selective attention as well (g = 0.15; 
Fernandez-Serrano et.al., 2011). Impulsive action and choice overactive in SUD. 
Evidence shows moderate effect sizes for impulsive action in methamphetamine and 
MDMA populations, impairments present in heroin, and alcohol populations as well 
(Table 2). Impulsive choice impairment was present in alcohol populations. 
Fernandez-Serrano et.al (2011) found moderate magnitude effects between both 
cocaine and MDMA populations and decision making, with impairments also present 
in heroin, and alcohol populations (Table 2). Mackillop, Amlung, Few, Ray, Sweet, 
& Munafo, (2011) found impairments in decision-making to be present in cocaine 
populations (See Table 6) however there is a gap in the literature exploring pure 
psychosocial interventions (Fernandez-Serrano et.al., 2011). Alcohol and MDMA 
studies found deficits in cognitive flexibility (Table 2). Two studies assessing 
cannabis and heroin polysubstance found impairments in cognitive flexibility as well 
(g = 0.38).  
Impairment effects on treatment outcomes  
	
Psychosocial therapies uses a range of cognitive-based treatments such as 
CBT and MET and are considered best practice for a range of use disorder types 
(Acosta, Marsch, Xie, Guarino, Aponte-Melendez, 2012; SAMHSA, 2016). 
However, researchers argue that cognitive deficits may interfere with a treatment 
seeker’s ability to engage in or benefit from these treatments (Lyvers, 2000).   
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Studies have found strong correlations between cognitive impairment and 
treatment dropout (Hagen et al., 2017).  In particular, cognitive processes that require 
individuals to regulate, control, and manage craving and drug seeking behaviors are 
paramount to treatment success. These neurocognitive mechanisms (top-down and 
bottom-up) make a meaningful contribution to clinical outcomes (Manning el.al., 
2017; Fernandez-Serrano, Perrales, Moreno-Lopez, Perez-Garcia, & Verdejo-Garcia, 
2012).  
Top-down processes are mechanisms that use prior knowledge to interpret 
contextual information (Freberg, 2010, Manning et. al.,2017), and include executive 
functions such as decision making, response inhibition, cognitive flexibility and 
executive control (SAMHSA, 2016). Bottom-up processes are mechanisms that 
control automatic and impulsive processes (Freberg, 2010), including	spontaneous 
memory association, attentional and approach bias toward substance-related stimuli 
(SAMHSA, 2016). As outlined previously, impairments in these areas have shown to 
be present in SUD populations (Fernandez-Serrano et.al., 2011) and linked to lower 
treatment retention (Manning, et. al.,20172017).  
 
Manning et. al. (2017) proposes that poor treatment outcomes may be 
associated with a combination of overactive bottom-up processes and underactive 
top-down processes. The theoretical framework proposed is shown in Figure 2.   
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Figure 2: Theoretical framework proposed by Manning el.al.(2017) adapted for the purposes of the 
study.  
Bottom-up Mechanism: Attentional Bias 
	
Evidence suggests hypersensitization of the meso-cortico-limbic reward 
pathways which drives incentive motivation (i.e. ‘wanting’) is responsible for this 
enhancement in bottom-up processes (Robinsone, & Berridge, 2000). Neuroimaging 
studies have found a reduction in hypersensitivity in this circuit when treatment is 
successfully implemented (Zilverstand et al, 2016). Hypersensitization is caused by 
strong classical and operant conditioned responses, as drug related stimuli are 
repeatedly paired with urge-related responding (Copersino, 2017). Prolonged drug 
use strengthens these associations, leading to cognitive biases toward substance 
related stimuli, making abstinence difficult (Copersion, 2017).  
12	
	
	
	
A meta-analysis of 69 studies found bottom-up processes to be associated 
with craving although demonstrate a small magnitude effect (r=.19; Field et al, 
2009). Bottom-up processes (cognitive bias) have also been associated with relapse 
and show a medium effect size (89 studies, r=.31; Rooke et. al., 2008). One aspect of 
cognitive bias presented in bottom-up processes is attentional bias. Attentional Bias 
refers to the automatic and subconscious attention, dependent individuals give to 
drug related stimuli over non-drug related stimuli (Sofuoglu, et. al., 2013). This 
cognitive mechanism has been associated with impulsivity (Nuijten, Blanken, Brink, 
Goudriaan & Hendriks,2016) and craving (Cox, Hogan, Kristian, & Race, 2002) and 
may contribute to associations found between attentional bias and relapse (Field & 
Cox, 2008, Sofuoglu et.al., 2013). A common way to assess this bias is through the 
use of the dot-probe task. The dot-probe task has links to prolonged attention and 
drug craving (Field & Coxs, 2008). Subjects are given a fixation point, presented 
with two stimuli which are subsequently removed, and then are then presented with a 
probe placed in the position that one of the stimuli had occupied previously (Figure 
3). Reaction times to probes that replace substance-related stimuli are compared with 
those that replace neutral stimuli.  
 
Figure 3:  Bottom-up Attentional Bias Dot-probe task. a)	fixation point. b) paired neutral with drug 
stimuli. c) response probe.   
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Substance-related stimuli are responded to much more rapidly than carefully 
matched neutral stimuli, therefore attentional bias for substance-related cues is 
inferred (Field, Munafo, & Franken, 2009). Evidence suggests greater attentional 
bias to be negatively correlated with severity of substance abuse (Field, Moog, 
Zetteler, & Bradley, 2004). Effect sizes for studies using the dot probe task or visual 
probe task (where the probe is a symbol instead of a dot) are shown in Table 3. Small 
to medium effect sizes can be seen using the dot-probe task to measure attentional 
bias in substance use disorder populations.  
 
Table 3  
Characteristics of studies using the dot probe task or visual probe task to measure 
Attentional Bias and Main effect sizes correlation with SUD severity. 
Author N Substance Task N of 
paired 
stimuli 
Length of 
presentation 
(ms) 
r SE 
Field, Eastwood, 
Bradley, and Mogg 
(2006) 
45 Cannabis VP 18 2000 .24 .15 
Field et. al. (2004) 40 Alcohol VP 14 Varied 
between	200, 
500, & 2000 
.41 .16 
Lubman, Peters, 
Mogg, Bradley, and 
Deakin (2000) 
32 Heroin DPP - 500 .35 .19 
Townshend and 
Duka (2001) 
32 Alcohol DPP 20 500 .37 .19 
Townshend and 
Duka (2001) 
32 Alcohol DPW 10 500 .06 .19 
Note: DPP= Dot Probe using pictures, DPW= Dot Probe using words VP= Visual 
Probe 
 
Literature suggests that attentional bias may be a cognitive marker for 
treatment dropout in cannabis population (Field, Marhe, Franken, 2014). 
Associations between attentional bias and treatment outcomes are mixed  (Leeman, 
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Robinson, Waters, & Sofuoglu, 2014). A study by Carpenter, Schreiber, Church and 
McDowell (2006) found greater attentional bias to cocaine stimuli to be associated 
with poorer treatment outcomes. On the other hand, study conducted by Capenter, 
Martinez, Vadhan, Barnes-Holmes, & Nunes (2012) found stronger attentional bias 
to cocaine stimuli to be correlated with greater treatment attendance rates (r = .51, p 
= < .05) and a greater proportion of cocaine-free urines (r = .49, p = < .05). Many 
studies assessing attentional bias, including those with positive findings (eg. Table 3) 
are underpowered and have been criticised for having methodological weaknesses 
and inconsistencies (Christiansen, Schoenmakers, & Field, 2015). Underpowered 
studies can yield false positive or null findings (Button et al., 2013).  Christiansen, 
Schoenmakers, and Field (2015) calls for standardised testing to be used, therefore 
this study will be modeled closely after their recommendations.  
Top-down Measure: Response Inhibition 
	
The theoretical framework underlying the cognitive mechanisms present in 
addiction show a constant tension between top-down (self-control) and bottom-up 
(urge-related) responding (Copersino, 2017). In contrast to the unconscious nature of 
bottom-up processes, top-down processes include high-order cognitive functioning 
such as metacognition and executive functioning (Copersino, 2017). Manning et.al. 
(2017) proposes diminished top-down processes to be predictive of poorer treatment 
outcomes and relapse. Drug related impairments to both the functioning of the 
dorsolateral prefrontal cortex (responsible for goal-directed behaviour) and 
orbitofrontal cortex (responsible for processing information about environmental 
contingencies) are attributed to diminished top-down/executive responding 
(Sofuoglu el.al., 2013).  
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The two most widely recognised components of neurocognitive impulsive 
behaviour are impulsive action and impulsive choice, the ability to control these 
urges are important for treatment success (Rupp el.al., 2016). Response inhibition 
refers to the ability to exhibit control over impulsive actions and is a strong predictor 
of treatment completion (Stevens, Goudrian, Verdejo-Garcia, Roeyers, & 
Vanderplasschen, 2015). The ability to withhold or stop a behavioural response and 
transition to a more appropriate behaviour is an important mechanism in overcoming 
SUD. As previously highlighted, impairments in response inhibition have been seen 
in SUD populations (Table 2). These impairments are also a criterion for substance 
use disorders in the DSM-5 (American Psychiatric Association, 2013), with the first 
four criterion focusing on a person’s difficulty to control/reduce drug use (see Table 
1). Response inhibition is often assessed via tasks such as the Stop-Signal Task 
(SST). In the SST, participants are prompted to respond to stimuli in a two-
alternative forced choice task, with a stop-signal presented very occasionally and at 
varying intervals after stimulus onset prompting participants to withhold their 
response after it has already been initiated (Figure 4). 
Figure 4: Top-down Response Inhibition Stop Signal task. a) left response. b) right response. c) left 
response followed by stop signal, presented initially 250ms and increasing or decreasing at 50ms 
intervals following correct or incorrect responses.   
	 	 	
(a)	 (b)	 (c)	
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 Poor performance in this task has shown associations with relapse and 
treatment drop-out in substance dependence, including cocaine (Fernandez-Serrano 
et.al.,2012), alcohol (Li, Luo, Yan, Bergquist, & Sinha, 2009) and methamphetamine 
(Monterosso, Aron, Cordova, Xu, & London, 2005). Evidence to suggest this task is 
associated with severity of SUD is also evident (Fernandez-Serrano el.al.,2012). 
Although clinical literature suggests cognitive impairments and poor inhibitory 
control are linked to drug treatment outcomes, studies reveal mixed results, as shown 
in Table 4.  Significant associations have been found between all illicit drugs 
included with small to moderate effect sizes, with the exception of cannabis.  
Table 4 
Weighted mean effect sizes (g) from meta-analysis conducted by Smith, Mattick, 
Jamadar, & Irsdale (2014) for stop signal task when compared to control group.  
Substance k g SE 95% CI z p 
Cocaine 9 0.464 0.08 0.29-0.64 5.24 <.001 
Methamphetamine 3 0.724 0.18 0.36-1.09 3.92 <.001 
Alcohol 6 0.395 0.09 0.23-0.56 4.61 <.001 
Cannabis 6 0.004 0.12 -0.23-
0.24 
0.04 .971 
Note: k = number of studies, SE = standard error.  
 
Impairments in decision making have also been seen in SUD populations 
(Table 2). Impulsive decision making is of particular interest to behavioural 
economics as it aims to understand choice behaviour under conditions of constraint 
(Mackillop et.al., 2011). The delayed Discounting task (DD), tests components of 
impulsive choice behaviour (Stevens, Verdejo-Garcia, Roeyers, Goudriaan, & 
Vanderplasschen, 2014) as it assesses an individual’s preference for immediate over 
delayed rewards. The task gives participants an option between a hypothetical 
monetary reward now or a larger reward after a delay period. Monetary rewards are 
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between $11-85 with the delay being between 7-186 days. For example, “would you 
prefer $54 today, or $55 in 117 days?”. Meta-analysis has found DD to be associated 
with severity of substance use (Yi, Mitchell, & Bickel, 2010). A meta-analysis 
showed, when compared to control groups, participants with SUD preformed poorer 
(Mackillop et al, 2011). Table 6 shows results of the meta-analysis conducted by 
Mackillop et al, (2011) with small to medium effect sizes across studies.  
 
Table 6 
Results of Meta-analysis conducted by Mackillop et al, (2011) showing comparisons 
of delayed discounting between SUD population (in-patient and out-patient) and 
control group.  
Sample k d Z p 
Overall Sample 57 0.58 17.17 <.0001 
Inpatient Studies      
Alcohol  9 0.50 5.87 <.0001 
Stimulant  6 0.87 6.78 <.0001 
Opiate  3 0.76 5.57 <.0001 
Cannabis  1 0.20 0.71 .480 
Outpatient Studies     
Alcohol 5 0.26 2.11 <.05 
Note: Overall sample included tobacco (17), gambling (7), & mixed 
 
Fewer studies have explored the relationships between DD and early-dropout 
rates, with much focus on DD as a predictor of relapse (Peters, Petri, LaPaglia, 
Reynolds, & Carroll, 2014; Stevens el.al., 2014). Studies which show significant 
associations between DD and treatment outcomes are represented in table 7. 
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Table 7 
Standardised coefficients (β) and characteristics of studies using a delayed 
discounting task to treatment outcomes.  
Studies N Substance k value Outcome Measure ß 
Peters et.al. (2014) 127 Marijuana Overall Percent days of 
marijuana abstinence at 
follow-up (12 months) 
.01 
Stevens et.al. (2015) 84 Any In overall  Still in Inpatient 
treatment at 1 month 
-4.50 
Stranger et.al. (2014) 165 Marijuana In overall  Continued abstinence at 
1 month  
-.020 
Passetti et.al. (2010) 48 Opioid Logistic  Still in treatment (3 
months)  
-3.33 
 
Relapse rates may be a by-product of treatment engagement, therefore 
exploring relationships between DD and early-dropout rates may bridge a gap in the 
literature and lead to further insight into how one should conduct interventions. 
Given that out-patient therapy is largely based around cognitive behaviour therapy 
and goal setting, the ability to choose long term progress rather than immediate 
gratification is necessary for therapy success. Individuals who drop-out of treatment 
after less than 3 months, have been shown to have a higher likelihood of choosing 
immediate rewards (Stevens el.al, 2015).   
Other Predictors of Treatment drop-out 
	
There has been much research into individual factors contribute to relapse 
rates in out-patient talk-based therapy (Turner, LaRowe, Horner, Herron, & 
Malcome, 2009; Stevens et.al., 2015), but there is a lack of an overarching 
theoretical framework. A systematic review conducted by Brorson, Arnevik, Rand-
Hendriksen & Duckert (2013) identified a large number of correlates of dropping out 
from addiction treatment, including several patient factors such as younger age, 
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female gender, lack of motivation, lower education and lower socioeconomic status. 
Brorson et al (2013), also identified treatment factors such as the treatment setting 
(residential or out-patient), non-pharmacotherapy, court mandated treatment, 
program duration and therapist qualities. SUD has also been associated with higher 
self-reported measures of trait impulsivity (Li et al., 2006; Monterosso et al., 2005). 
A study by Stevens et.al. (2015) however, found when compared to trait impulsivity, 
impulsive behaviour was a better predictor of treatment relapse.  
Many factors associated with treatment outcomes of SUD are correlated with 
each other. Samuel, Carroll, Canning-Ball and Rounsavillle (2006) found trait 
impulsivity and treatment readiness to be significantly associated with early 
treatment drop-out (first month). Treatment drop-out in SUD populations have also 
found to be associated with impulsivity (Nuijten et.al.,2016) and craving (Cox et.al., 
2002). As both the DD and SST are recognised components of neurocognitive 
impulsive behaviour, it is logical to suggest trait impulsivity to be a potential factor 
in treatment engagement and early dropouts. As previously stated, both components 
have shown to be strong predictor of treatment completion (Stevens et.al., 2015).  
SUD and depression and anxiety show a high comorbidity, with studies 
showing significant negative impacts of these affective disorder and both symptom 
severity and treatment outcomes (Lubman, 2015; Brorson et al, 2013).	Wills and 
Hirky (1996) propose that SUD may be a coping mechanism for psychological 
distress.  Literature surrounding the comorbidity of depression and substance abuse 
is lacking in adult populations and results are mixed. Some studies show an 
association between depression, substance abuse and cognitive impairments 
(Lubman, 2015). However, Pencer & Addington (2003) found in a sample of 
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individuals with comorbid depression and mild-to-moderate substance abuse 
disorders, participants did not exhibit more cognitive impairment than those who are 
diagnosed with just depression. Evidence also shows associations between 
personality disorders and early treatment drop out (Brorson et al, 2013).  
It is difficult to assess the underlying causes of treatment drop-out in SUD. 
There is a wealth of literature into individual factors associated with poor treatment 
outcomes, however a lack of overall synthesis. Studies that show strong correlations 
between a specific factor (e.g. psychological distress, impulsivity, cognitive deficits) 
and treatment outcomes often fail to control for other potential factors that have 
shown to be correlated with outcome. Mixed results between studies assessing 
cognitive deficits and treatments outcomes may be due to a lack of comprehensive 
control for other predictive factors.  
This Study 
	
This study aims to better explore the relationship between relapse rates and 
cognition. It aims to compare cognitive assessments that have been associated with 
treatment outcomes, in particular, attentional bias via a dot probe task (a bottom-up 
process), response inhibition via a stop signal task and decision making via a delayed 
discounting task (top-down processes) as predictors of treatment outcome. This 
study’s primary hypothesis is that poorer performance in these cognitive tasks 
(greater substance use attentional bias, poorer inhibitory control, and greater 
emphasis on short term outcomes) will be associated with poorer treatment 
engagement (less attendance) at one-month follow-up, thus consistent with the 
theoretical framework proposed by Manning et.al. (2016). In addition, this study will 
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explore the severity of substance abuse disorder as a correlate of these cognitive 
measures, as this is also a key proposal underlying the Manning et al (2016) model.  
The secondary hypothesis is that participants who have more symptoms of substance 
use disorder will show poorer performance on these cognitive tasks.  
Method 
Participants  
 
Experiment one: Cognition in Treatment (CTx) Study 
	
Seven participants were recruited: Four experiencing problems with alcohol, 
and one each with cannabis, opioids, and methamphetamine. All were outpatients 
currently in ‘talk-based’ treatment for substance use problems; exclusion criteria are 
summarised in Table 8.  
Recruitment occurred via advertisements placed at drug treatment services across 
Hobart (Holyoake, Anglicare, The Link Youth Health Service, Salvation Army 
Bridge Program, Alcohol and Drug Services). Participants responded to 
advertisements by either completing a screening survey online or via telephone. 
Participants reimbursed $40 to compensate for time and out-of-pocket expenses. 
Ethical approval was provided from the Tasmanian Social Sciences Human Research 
Ethics Committee (#H0017170; See Appendix C for full report).  
22	
	
	
	
Table 8  
Exclusion criteria for Experiment 1 and 2 
Exclusion Criteria  Ex1 Ex2 
Under 18 years * * 
Non-English speakers * * 
Pharmacotherapy for substance problems (e.g. methadone) * * 
Inpatient treatment * * 
Current medical/inpatient withdrawal for substance use *  
Presence of comorbid licit or illicit SUDs (nicotine or caffeine not 
included) 
 * 
First time in treatment  * 
Court mandated to attend treatment  * 
Pregnant/lactating females  * 
 
Experiment 2: Sativex Trial 
	
Due to difficulties with recruitment, existing data from 67 participants 
randomised to the placebo group for a trial of nabiximols (Sativex®) for cannabis 
use disorder (Bhardwaj et al., 2018) were analysed to investigate the hypotheses. 
Participants were recruited from four addiction medicine centers in New South 
Wales. Participants were aged between 18 and 65 years old, seeking treatment for 
cannabis use disorder, and had not responded to at least one prior attempt at 
treatment for their cannabis use. Exclusion criteria presented in Table 8. Participants 
were recruited through referrals from drug and alcohol treatment services, media 
advertisements and the University of Sydney website. Ethical approval was provided 
by the Human Research Ethics Committee of South East Sydney Local Health 
District (HREC/14/POWH/701).   
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Materials  
 
Table 9 
Measures used to operationalise the constructs in the two studies 
Construct Experiment 1: CTx Experiment 2: Sativex 
Bottom-up drive strength 
 
Attentional bias dot probe 
 
Marijuana Craving 
Compulsivity Scale 
Top-down inhibitory 
processing 
Stop Signal Task 
Delayed Discounting 
MCQ 
Stop Signal Task 
Consumption of target 
drug 
Timeline Follow-back Timeline Follow-back 
Substance use disorder 
symptoms  
AUDAIS-5 CPQ 
General cognitive 
function 
MOCA 
WTAR 
WTAR 
Psychological distress Kessler 10 DASS 
Readiness to change SOCRATES  
Trait Impulsivity Eysenck I7 Impulsivity  
BIS/BAS Reward  
 
Treatment Outcomes Still attending treatment 
at week 4  
Still attending treatment 
at week 4 and 12 
 
Operationalisations of bottom-up drive strength 
	
Attentional bias dot probe (DP). This was modelled after Miller and Fillmore 
(2010). Participants are required to quickly identify the location of a probe target 
(left or right). The probe is presented in one of two locations that have just had 
substance use-related or matched neutral stimuli presented. Ten	substance use stimuli 
were paired with 10 neural stimuli which looked similar in structure, e.g. beer paired 
with soft-drink (See Appendix D for stimuli). Substance use stimuli were chosen to 
relate to the participant’s problem substance (amphetamines, cannabis, alcohol or 
opioids). When compared to general drug paraphernalia (syringe, lighter, spoon etc.) 
internal reliability is higher when stimuli are personalised to an individual’s main 
substance of concern (Christiansen, Mansfield, Duckworth, Field, & Jones, 2015). 
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All pictures were presented four times, for a total of 80 trials. A fixation point of 
500ms begun each trial, followed by 1000ms of the paired items at the left and right 
of the screen. An arrow probe followed and presented either at one of the stimuli 
locations, with these locations counterbalanced. It remained on the screen for a max 
of 1000ms until the participant responded to the direction of the probe. Attentional 
Bias was calculated in milliseconds using the mean of Dot Probe Reaction Time 
(DPRT) for incongruent trials (probe and neutral stimuli same position) and 
congruent trials (probe and drug stimuli same position).  
 
Marijuana Craving Compulsivity Scale (MCQ). The MCQ assesses four 
aspects of cannabis craving (compulsivity, emotionality, expectancy and 
purposefulness) on a 7-point Likert scale, from 1 = strongly disagree to 7 = strongly 
agree. The seven item compulsivity subscale was chosen as a proxy for bottom-up 
drive, as the content of these items reflect the automatic, stimulus driven nature of 
bottom-up processes (See Table 10). The MCQ has shown to be a valid and reliable 
test of compulsivity in marijuana use populations (r=.82; Heishman, Singleton, & 
Liguori, 2001). 
Table 10 
MCQ Compulsivity factor structure.  
Item Factor 
Loading 
If I smoked a little marijuana right now, I would not be able to stop using 
it. 
0.59 
I would do almost anything for a joint. 0.55 
It would be difficult to turn down a joint right this minute. 0.50 
Starting now, I could go without smoking marijuana for a long time. 0.40 
I would not be able to control how much marijuana I smoked if I had some 
here. 
0.64 
I could easily limit how much marijuana I smoked right now. 0.63 
I do not need to smoke marijuana right now. 0.72 
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Operationalisations of Top-Down Inhibitory Processing 
	
Stop Signal Task (SST). This tests participant reaction time in response to 
target stimuli in a two-alternative forced choice reaction time paradigm. Participants 
were instructed to touch a left or right square as quickly as possible in response to a 
visually presented letters X or O, respectively. Occasionally there was a stop signal 
presented (X) after a short delay following stimuli presentation. Timing between the 
first trial and the stop signal was 250ms, with the following trials increasing or 
decreasing by 50ms depending on response correctness. Stop signal reaction time 
(SSRT) was recorded as the measure of response inhibition. The SSRT is defined as 
the minimum delay in which participants can inhibit their response to stop signals 
50% of the time (calculated by subtracting stop signal delay from the mean go signal 
reaction time). This task included a starting fixation point of 500ms and ran 48 trials 
with 25% being stop signal trials.  
 Delay Discounting Task (DD). Created by Kirby, Petry, and Bickel (1999), 
the DD (27 questions) used a monetary choice questionnaire to assess delay 
discounting. Questions consists of a choice between an amount of money now or a 
larger amount later. Monetary rewards ranged between $11-85 with delay ranging 
between 7-186 days. For example, “would you prefer $54 today, or $55 in 117 
days?” The Mazur, 1987 hyperbolic discounting model was used to calculate overall 
rate of discounting and produce a k value for each monetary group and one based on 
participant’s overall responses. The k values are calculated using the formula, != "1+#$ (V= magnitude of the immediate reward, A= magnitude of the delayed 
reward, and D= length of the delay for that item). In differentiating between patients 
with heroin dependence and control subjects, the MCQ has demonstrated strong 
construct validity (Kirby et. al., 1999).  
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Covariates  
Timeline Follow-back (TLFB). The TLFB (Sobell and Sobell, 1992), asks 
participants to provide self-reported information regarding their days of substance 
use in the month prior to assessment. It provides a systematic recall-supporting 
framework to support individuals to retrospectively recall patterns, quantitative 
measures and variability of substance use over the past 28 days. A systematic review 
found when compared to biological samples, TLFB validly detects use of illicit 
substances in populations with SUD between r=.72 to r=.85. (Hjorthoj, Hjorthoj 
&Nordentoft, 2012).   
 
 Alcohol Use Disorder and Associated Disabilities Interview Schedule-5 
(AUDADIS-5). The AUDADIS-5 is a standardised structured approach to identify 
SUD criteria in concordance with the DSM-5 (Hasin et al, 2015), designed for 
application in epidemiology surveys. The questions are used to assess the presence of 
SUD criteria in the 12 months prior to interview. The measure has demonstrated 
good to excellent validity (Duresso, Matthews, Ferguson, & Bruno, 2016). 
 
Cannabis Problems Questionnaire (CPQ, Copeland, Gilmore, Gates, & 
Swift,2005). The CPQ is a	27 item scale with responses scored on a 11-point Likert 
scale (0 = doesn’t apply to me to 10 = strongly apply to me). The CPQ measures 
acute and physical, psychological, and social consequences of cannabis use.  
Significant positive correlations were found between total CPQ score and the number 
of DSM-IV SUD symptoms in cannabis consumers (r= .72; Copeland,	Copeland, 
Gilmour, Gates & Swift, 2005).   
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Wechsler Test of Adult Reading (WTAR). The WTAR	consists of 50 words 
that have irregular grapheme-to-phoneme correspondence. Participants are asked to 
read these words aloud and the correctness of each pronunciation is recorded. The 
WTAR was co-normed with the Wechsler Adult Intelligence Scale 3rd Edition and 
provides a close estimate to these IQ values (r = .84; Green et. al., 2008).  
 
Montreal Cognitive Assessment (MOCA). The MOCA is a brief screening 
tool for cognitive impairment, assessing domains of attention, concentration, 
executive functions, memory, language, visuospatial ability, conceptual thinking, 
calculations, and orientation, with a total score of 30. It has been been widely used 
and validated as a screening tool for cognitive problems in substance dependent 
populations (Marceau, Lunn, Berry, Kelly, & Solowij, 2016).  
 
Kessler-10 (K10, Kessler, Andrews, & Colpe, 2002). This assesses 
psychological distress, and consisting of 10-items scored on a 5-point Likert scale 
(1= None of the time to 5=All of the time) asking the participant to rate symptoms in 
the past 4 weeks. Each item is therefore scored out of five with the maximum score 
being 50, indicating severe distress, and the minimum score is 10, indicating no 
distress. The scale has been well validated in SUD populations. In a validation study 
of the K10, more than 90% of an Australian general population sample scoring more 
than 30 on the K10 met criteria for an ICD-10 disorder (Andrews & Slade, 2001).  
 
Depression, Anxiety and Stress Scale Short-form (DASS, Lovibond & 
Lovibond, 1995). The DASS is a 21 item questionnaire using a 4-point Likert scale 
(0= does not apply to 3= applied to me very much), assessing severity of depression, 
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anxiety and stress.  Depression and anxiety scores were used given the conceptual 
relationship with psychological distress assessed in the K10. The DASS21 
depression scale demonstrated a correlation of 0.79 with the Beck Depression 
Inventory and the DASS 21 anxiety scale has a correlation with 0.85 with the Beck 
Anxiety Inventory in a clinical sample (Antony et al, 1998) 
 
Stages of Change Readiness and Treatment Eagerness Scale (SOCRATES, 
Miller & Tonigan, 1996). This is a 19 item scale assessed with 5-point Likert items 
(anchors strongly disagree; strongly agree). It is designed to assess readiness to 
change in those with substance dependence and consist of three factors, recognition, 
ambivalence and engagement to change, reflecting the transtheoretical model of 
Prochaska and DiClemente (DOH, 2004). High positive correlations have been 
identified between baseline measures of SUD and ambivalence (r = .88), recognition 
(r = .96), and Taking Steps (r = .94; Williams & Tonigan, 1996).  
 
Eysenck Impulsivity Subscale (I7; Eysenck, Pearson, Easting, & Allsopp, 
1985). The 17 is a subscale of the Eysenck’s Impulsivity Inventory which measures 
personality traits of impulsivity, venturesomeness, and empathy. The 19 item 
subscale scale focus on impulsivity and requires yes/no (coded 1 & 0) response. 
Maximum score on the scale is 19, with higher scores indicating higher levels of trait 
impulsivity (validity). The 17 has shown to hold both cross-cultural validly and 
generalisability across sexes (Russo, Leone, & Pascalis, 2011).  
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Procedure  
 
Experiment 1 (CTx):  
Participants were tested at 1.5hr sessions at the Psychology Research Centre 
at the University of Tasmania. Participants were screened for eligibility though an 
online survey. Demographics and all scale scores were collected in an online 
RECDAP database (Table 11). The cognitive tests were conducted using Inquisit 
web (offline) on iPad and Penscreen software on android tablets. Batteries were 
conducted in standardised order. A follow up phone call to participants was also 
conducted 4 weeks from date of initial treatment. Participants were asked if they 
were still attending sessions at their service provider.  
 
Table 11 
Order of Experimental 1 procedure  
n Measure Data collection method 
1 Informed Consent for Baseline, 1 month and 3 
month follow-up  
Manual 
2 Demographics and Baseline craving  REDCAP 
3 Time Line Follow Back REDCAP 
4 Drug Q-score REDCAP 
5 AUDADIS-5 REDCAP 
6 Cued Craving REDCAP 
7 WTAR REDCAP 
8 Cognitive battery 1:  
             Dot Probe Task * 
             Iowa Gambling Task 
             Emotional Stroop 
Millisecond software 
9 Delay Discounting Task * REDCAP 
10 Cognitive battery 2:  
             Go no Go Flankers 
             N Back 
             Stop Signal Task* 
PenScreenSix Cognitive 
Testing Software v1.6 
11 MoCa REDCAP 
12 SOCRATES REDCAP 
13 K10 REDCAP 
14 Eysenck 17 Impulsivity Scale  REDCAP 
15 BIS/BAS Scale  REDCAP 
Note: * Cognitive measures used in this study   
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Experiment 2 (Sativex)  
 
Participants were receiving placebo in a 12-week drug trial. All participants 
also received individual counselling over this period, consisting of CBT, withdrawal 
management and relapse prevention with participants required to attend a minimum 
of two sessions. All participants also received followed-up research interviews, at 4 
and 12 weeks. Retention at each of these time points was used as the outcome 
measure for this study. Full study protocol can be found in Bhardwaj et. at. (2018).  
 
Design 
A correlational design was employed for both experiments. Due to sample 
size, only correlations were conducted in the CTx study. For analysis of the Sativex 
trial data both Pearson correlations and hierarchical linear regression models were 
used to	test	the	first	hypothesis	(whether	cognitive	measures	are	associated	with	
SUD	severity).	Hierarchical logistic regression models were also conducted with 
Sativex trial data to examine the second hypothesis (whether cognition is associated 
with treatment outcomes). The outcome variables were dependence (indexed by 
CPQ) and treatment drop out (by week 4 or by week 12). Independent variables were 
SST RT and MCQ compulsivity. SST RT data was examined for outliers, and two 
participants reported extreme scores (>2SD from group mean), both of whom also 
had extreme dependence scores. However, when these participants were removed 
from analyses, no substantial differences were identified in results so these 
participants were retained. Analyses with removed participants are available in 
Appendix F.  Power analysis estimates based on these hierarchical linear regression 
models to provide a R2 of 0.1-0.2, required a minimum of 52 participants for reliable 
(power=.80) identification of a statistically significant effect (α =.05).   
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Results 
Experiment 1: CTx  
	
Seven participants, with a mean age of 41.7 (range 25-61) were included. 
Participants were experiencing AUDADIS-5 assessed moderate to severe SUD with 
a mean DSM-5 symptom count of 7.7 out of 11 (range = 4-10).  
 
Pearson correlations identified no statistically significant correlations 
between cognitive performance, and severity of dependence or any covariates (Table 
12). Results revealed all relationships were non-significant. Bottom-up drive (DPRT) 
showed a weak negative linear relationship with dependence measure. A weak 
positive relationship was found between SSRT and dependence. A moderate positive 
relationship was found between DD measure and dependence. DD showed weak 
negative relationship with WTAR, indicating higher discounting was associated with 
lower measures of pre-morbid cognition. SSRT showed a weak positive relationship 
with WTAR and a strong positive relationship with MoCa, both measures of pre-
morbid cognition. DPRT showed moderate negative relationships with both 
ambivalence and trait impulsivity.  A moderate positive relationship was found 
between DD and psychological distress. Weak negative relationships were found 
between psychological distress and both DPRT and SSRT. Significant positive 
correlations were also found between dependence and psychological distress (r = 
.842, p < 05) and readiness to change (r = .893, p <.01). Correlations between other 
covariates are reported in Appendix E.  
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Table 12  
Pearson Correlations between cognition (Top-down Inhibition & Bottom-up Drive) 
and covariates in experiment 1 
Variables Bottom-Up 
(DPRT ms 
incongruent) 
Top-Down 
(SSRTms) 
Top-Down 
(DD log k) 
r r r 
Bottom-Up (DPRTms incongruent) - 0.58 0.12 
Top-Down (SSRTms) - - 0.41 
Top-Down (DD log k) - - - 
Dependence (DSM symptom count) -0.10 0.29 0.52 
WTAR -0.06 0.31 -0.35  
MoCa 0.38 0.66 0.31 
Psychological Distress (k10) -0.29 -0.30 0.55 
Readiness to change - SOCRATES recognition -0.38 -0.26 0.38 
Readiness to change - SOCRATES ambivalence -0.44 -0.05 0.17 
Readiness to change - SOCRATES taking steps -0.36 0.05 -0.21 
Impulsivity (I7) 0.45 -0.20 0.21 
Note: *p < .05, **p < .01  
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Bottom-up Drives Attentional Bias Dot Probe relationship with Dependence 
	
Figure 5 shows correlations between dependence and bottom-up measure. 
The correlation between DSM-5 symptom count and DPRT was r = .29, p = .887. 
Although not significant, relationship shows a slight positive skew. This could 
suggest severity of SUD to be positively correlated to attentional bias.  
 
Figure 5: Scatter plot of individual participants Dot Probe and level of dependence  
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Top-down Inhibition Stop Signal Task (SSRT) relationship with Dependence 
	
SSRT Mean was 515ms (SD=154) with range of scores between 341ms and 
708ms. The correlation between DSM-5 symptom count and SSRT was r = .29, p= 
.587. Visual inferences and correlations were not significant (Figure 6). The two 
participants with the highest symptom count also indicated slowest response times. 
Previously. There were no outliers in the data as all SSRT scores fell under 2 
standard deviations.  
 
 
Figure 6: Scatter plot of individual participants SSRT and level of dependence  
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Top-down Decision Making Delayed Discounting relationship with Dependence  
  
k values for DD task were fitted to a logistic regression following procedures 
described in Wileyto et. al. (2004) with higher values indicating strong discounting 
and a preference for immediate rewards. Mean for overall log k was 0.03 (SD = 
0.03). When running validity checks, to control for malingering, one participant 
achieved an overall k value of 0.00, meaning they consistently chose delayed rewards 
over immediate rewards regardless of reward size. This participant’s data was 
therefore removed as they did not engage with the task. Correlation between DD and 
dependence was significant (r = 0.81, p = .049) upon removal (Figure 6; see 
Appendix E for all correlations). A significant positive correlation was also found 
between DD and SOCRATES measure of ambivalence (r = 0.90, p = .037).  
  
Figure 7: Scatter plot of individual participants Delayed discounting and level of 
dependence.  
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Due to difficulties in participant recruitment, and an absence of treatment 
outcome data, the sample size was small and hence the full set of hypotheses were 
not able to be examined in the limited time frame of the study. As such, existing data 
from a large clinical trial (Bhardwaj et al, 2018) was examined to further examine 
the hypotheses.  
 
Experiment 2 
	
Data from 67 participants (mean age 34.3 years, range 19.8-60.2) was 
included. As an initial examination of the potential role of cognitive performance and 
outcomes, participants who dropped out of the trial were compared with continuing 
participants on their baseline cognitive performance. For very early treatment 
dropouts (week 4), while non-significant, there were small-moderate magnitude 
negative differences between those continuing and dropping out (those dropping out 
had worse SSTRT, Cohen’s d=0.36) which smaller when later dropouts were 
included (by week 12: Cohen’s d=0.15). In terms of bottom-up drive strength, while 
not statistically significant, those that were very early treatment dropouts (by week 4) 
had compulsivity scores that were greater by a moderate magnitude than those that 
were retained (Cohen’s d=0.33), although this was not retained when later dropouts 
were included (by week 12: Cohen’s d=-0.14).  
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Table 13 
Mean, Standard deviation and Effect sizes for participants still in treatment at week 
4 and 12.      
Measure Retained Dropped out t ( p) BF01 d 
M SD N M SD N 
Top-down 
inhibition 
(SSRT, ms) 
Week 
4 
502.98 119.89 55 546.70 122.20 12 1.14 
(.259) 
.518 .363 
Week 
12 
500.70 108.11 30 11.30 5.88 37 0.62 
(.541) 
.296 .325 
Bottom-up 
drives 
(compulsivity) 
Week 
4 
9.73 4.73 55 519.00 130.68 12 1.02 
(.312) 
.467 .151 
Week 
12 
10.4 4.26 30 9.70 5.48 37 -0.57 
(.570) 
.289 -
.140 
 
One of the key aspects of the theoretical framework is that the extent of top-
down inhibitory impairment and bottom-up drive enhancement should be related to 
the extent of dependence (Table N). There were moderate-small magnitude 
correlations between both the operalisation of bottom-up drive (compulsivity) and 
top-down inhibition (SSTRT) and dependence (CPQ; r = .30, p < .01; r = -.19, p = 
.109 respectively). DASS Anxiety was also significantly associated with both 
dependence and the cognitive measures (r = 0.31, p < .05 with bottom-up drive; r = 
.33, p < .01 with top-down inhibition; and r = .556, p < .01 with CPQ dependence 
respectively). Correlations between other covariates used in this study are reported in 
Appendix F.  
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Table 14 
Pearson Correlations between cognition and covariates in Experiment 2 
	 Bottom-Up	
(Compulsivity)	
Top-Down	
(SSRTms)	
Variables	 r	 r	
Bottom-Up	(Compulsivity)	 -	 -0.22	
Top-Down	(SSRTms)	 -	 -	
Dependence	 0.31**	 -	0.19		
Baseline	Substance	use	 0.12	 -	0.07	
WTAR	 -	0.43	 0.12	
Anxiety		 0.31*	 -0.33**	
Depression	 0.18	 -	0.20	
Readiness	to	change	 0.36**	 -	0.28*	
Still	in	treatment	week	4	 -	0.12	 -	0.14	
Still	in	treatment	week	12	 0.07	 -	0.08	
Note: *p < .05, **p < .01 
 
To assess the validity of SSRT and control for malingering. Two participants 
fell under 2 standard deviations below the mean (0.8). Both participants also showed 
severe dependence scores (195 & 111 out of 297). When omitted from analysis, there 
was no meaningful difference to the models or correlations, therefore participants 
were retained. Analysis with low scoring participants removed can be seen in 
Appendix F. All items of the compulsivity measures were answered, with no missing 
cases.   
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Table 15 
Hierarchical linear regression of associations between dependence and cognition  
	 Bottom-UP	
(Compulsivity)	
	 Top-Down		
(SSRTms)	
Variable	 t	 p	 R2	 	 t	 p	 R2	
Model	1	 	 	 .123	 	 	 	 .040	
Dependence	 2.97	 .004*	 	 	 -1.61	 .112	 	
Model	2	 	 	 .125	 	 	 	 .054	
Dependence	 2.96	 .004*	 	 	 -1.63	 .109	 	
WTAR	 -0.41	 .682	 	 	 0.96	 .341	 	
Model	3	 	 	 .164	 	 	 	 .129	
Dependence	 1.84	 .071	 	 	 -0.12	 .905	 	
WTAR	 -0.57	 .572	 	 	 1.01	 .318	 	
Depression	 -0.78	 0.44	 	 	 -0.00	 .998	 	
Anxiety	 1.67	 .101	 	 	 -2.13	 .037	 	
Note: * Significant result, p < .01.  
 
To further examine whether the theorised relationship between cognitive 
impairment and severity of dependence symptoms was retained after controlling for 
potential covariates, a series of hierarchical linear regression models were conducted 
(Table n). Relevant assumptions of this statistical analysis were tested and met. 
Collinearity statistics (i.e., Tolerance and VIF) were all within accepted limits, the 
assumption of multicollinearity was deemed to have been met. Residual and scatter 
plots indicated the assumptions of normality, linearity and homoscedasticity were all 
satisfied. Covariates were steadily included in analyses in steps, initially controlling 
for general cognitive function (WTAR) and then psychological distress (DASS 
depression and anxiety). Greater bottom up drives were significantly related to 
dependence after controlling general cognition and fell just short of traditional cut-
offs after controlling for psychological distress, thus providing some support for the 
theoretical framework proposed by Manning et. al. (2017). Contrary to Manning et. 
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al. (2017), however, strength of top-down drives did not show a statistically 
significant association with dependence in any of the models examined. 
In order to determine whether the proposed theoretical model was predictive 
of outcome, a set of hierarchical logistic regression models were conducted, whereby 
it was examined if poorer ‘top-down’ inhibitory cognition and greater ‘bottom-up’ 
drives predicted poorer treatment outcomes (early drop out; Table n). Relevant 
assumptions of this statistical analysis were tested and met. Collinearity statistics 
(i.e., Tolerance and VIF) were all within accepted limits, the assumption of 
multicollinearity was deemed to have been met. All interactions between raw scores 
and logit had significance values greater than 0.5, indicating that the assumption of 
linearity of the logit were met.  
For both early (by week 4) and later (by week 12) treatment dropout, neither 
cognitive measure was significantly associated with these outcomes, and the 
estimates of effect size (R2) were largely trivial or of small magnitude (Table N). 
While not significantly or meaningfully associated independently with early drop-
out, the top-down (SST RT) measure was a statistically significant correlate of week 
4 treatment disengagement after controlling for other key correlates of treatment 
dropout (e.g. psychological distress, baseline use and treatment readiness.   
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Table 16 Hierarchical logistic regression of associations between cognition and 
treatment outcomes  
Note: * Significant result, p = .05  
Variable	 Week	4	 	 Week	12	
Odds	
ratio	
95%	CI	 p	 R2	 	 Odds	
ratio	
95%	CI	 P	 R2	
Model	1	 	 	 	 .031	 	 	 	 	 .001	
Top-down	
(SSRT	ms)	
.991	 (0.99-1.00)	 .291	 	 	 1.00	 (0.99-1.00)	 .813	 	
Model	2	 	 	 	 .025	 	 	 	 	 .000	
Bottom-up	
(Compulsivity)	
.936	 (0.83-1.06)	 .309	 	 	 1.03	 (0.93-1.14)	 .564	 	
Model	3	 	 	 	 .085	 	 	 	 	 .003	
Top-down	
(SSRT	ms)	
.996	 (0.99-1.00)	 .185	 	 	 1.00	 (0.99-1.00)	 .864	 	
Bottom-up	
(Compulsivity)	
.902	 (0.78-1.04)	 .153	 	 	 1.02	 (0.91-1.13)	 .769	 	
Model	4	 	 	 	 .145	 	 	 	 	 .006	
Top-down	
(SSRT	ms)	
.997	 (0.99-1.00)	 .280	 	 	 1.00	 (0.99-1.00)	 .821	 	
Bottom-up	
(Compulsivity)	
.890	 (0.77-1.03)	 .111	 	 	 1.02	 (0.92-1.13)	 .740	 	
WTAR	 .955	 (0.90-1.02)	 .161	 	 	 1.01	 (0.97-1.04)	 .695	 	
Model	5	 	 	 	 .170	 	 	 	 	 .055	
Top-down	
(SSRT	ms)	
.995	 (0.99-1.00)	 .196	 	 	 0.99	 (0.99-1.00)	 .594	 	
Bottom-up	
(Compulsivity)	
.901	 (0.78-1.04)	 .168	 	 	 1.04	 (0.93-1.16)	 .544	 	
WTAR	 .960	 (0.90-1.02)	 .196	 	 	 1.01	 (0.97-1.05)	 .554	 	
Depression	 1.035	 (0.92-1.17)	 .577	 	 	 0.88	 (0.73-1.05	 .156	 	
Anxiety	 .880	 (0.69-1.13)	 .308	 	 	 1.05	 (0.96-1.15)	 .279	 	
Model	6	 	 	 	 .390	 	 	 	 	 .097	
Top-down	
(SSRT	ms)	
.990	 (0.98-1.00)	 .052
*	
	 	 0.10	 (0.99-1.00)	 .471	 	
Bottom-up	
(Compulsivity)	
.985	 (0.82-1.18)	 .872	 	 	 1.06	 (0.94-1.20)	 .327	 	
WTAR	 .955	 (0.96-1.02)	 .155	 	 	 1.01	 (0.97-1.06)	 .499	 	
Depression	 1.025	 (0.87-1.20)	 .758	 	 	 0.90	 (0.74-1.08)	 .246	 	
Anxiety	 .860	 (0.66-1.13)	 .278	 	 	 1.06	 (0.95-1.18)	 .286	 	
Dependence	 .491	 (0.21-1.14)	 .097	 	 	 0.98	 (0.94-1.02)	 .396	 	
Baseline	
cannabis	use	
.996	 (0.97-1.03)	 .786	 	 	 0.99	 (0.98-1.02)	 .851	 	
Readiness	to	
change	
.956	 (0.89-1.03)	 .216	 	 	 0.94	 (0.84-1.06)	 .319	 	
42	
	
	
	
Discussion 
The present study was conducted to test the theoretical framework proposed 
by Manning et al (2017) and examined the relationship cognitive mechanisms (top-
down and bottom-up) have, with both severity of dependence and treatment 
outcomes. Results of the study were mixed, showing some support for the framework 
proposed.  
Manning et al (2017) suggest that the extent of top-down inhibitory control deficits 
and strength of bottom-up drives should be related to severity of substance use 
disorder – was this supported?  
Associations between bottom-up drives and severity of SUD 
 
Greater bottom-up drives (attentional bias) failed to show statistically 
significant correlations with severity of dependence in CTx. Participants took longer 
to respond to neutral stimuli in the presence of drug related stimuli. These results 
could be due to insufficient power. A relationship may be present in a larger sample 
size, as scatterplot showed a slight positive skew in data. Previous literature has been 
criticised for being underpowered and having methodological weaknesses 
(Christiansen et. al., 2015), and certainly low power was present here. Multiple 
independent studies have demonstrated a positive relationship between severity of 
attentional bias and substance use disorder (Field et. al., 2004; Field et. al., 2006; 
Lubman et. al., 2000, Townshend & Duka, 2001). However, Christiansen et.al. 
(2015) reviewed the relationship between attentional bias and relapse in a sample of 
alcohol, cannabis and cocaine users, and found mixed results.   
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In the Sativex trial, significant positive associations were identified between  
dependence severity and the bottom-up measure (MCQ compulsivity); however 
these had small magnitude effect sizes. This magnitude is similar to previous results.  
Heishman et. al., (2001) found associations between compulsivity and severity of 
SUD to be trivial in magnitude (r =.18).  Compulsivity is an underlying mechanism 
involved in craving (a criterion for SUD in the DSM-5; Hasin et al., 2013), and is a 
theoretically valid operationalisation of the automatic, stimulus driven nature of 
bottom-up processes. These findings provide some support for the theoretical 
framework under study and indicate a relationship between greater bottom-up drives 
(compulsivity) and SUD.  
Associations between Top-down inhibitory control measures and severity of SUD 
 
Poorer top-down inhibitory control displayed some small to medium 
significant relationships with SUD severity at baseline. In the CTx a significant 
strong positive correlation between performance in the delayed discounting task and 
dependence was apparent, whereby participants with greater number of DSM-5 
dependence symptoms had higher discounting scores and a preference for immediate 
rewards. These results are consistent with previous findings (Yi et. al, 2010; 
Mackillop et al, 2011) and provides supportive evidence for the proposed theoretical 
framework.  
The SST measure of response inhibition, however, failed to show significant 
correlations with severity of dependence in either study, contrary to the predictions 
of the theoretical framework.  While poor response inhibition is a criterion for 
substance use disorders in the DSM-5 (American Psychiatric Association, 2013), a 
44	
	
	
	
wealth of research with substance using populations using the SST to operationalise 
inhibitory control has shown quite mixed results (Li et. al., 2009; Fernandez-Serrano 
et.al.,2012, Monterosso et. al., 2005). The recent meta-analysis conducted by Smith 
et. al. (2014) is consistent with the findings here. Very small magnitude and non-
significant mean effect sizes were demonstrated for SST when comparing cannabis 
consumers to controls (see Table 4). Of note, in this analysis, cannabis alone was the 
only substance that was not associated with a significant SST effect, with significant, 
small to medium effect sizes apparent for all other illicit drugs studied (Smith et. al., 
2014).  
However, the absence of an effect may relate to the nature of the SST, 
particularly as operationalised in the current study. The meta-analysis conducted by 
Fernandez-Serrano et. al. (2011) demonstrates that response inhibition impairments 
are clearly present in cannabis consuming populations. Critical reviews of the 
paradigm have demonstrated that the procedures used to derive the SST RT can have 
a substantial difference on estimates of inhibitory control from the task (Boehler, 
Appelbaum, Krebs, Hopf, & Woldorff, 2012) and the methodology applied here was 
brief (approximately 3 minutes) with limited opportunity for inhibition with only 12 
stop signal trials. In previous implementations of this exact paradigm the sensitivity 
of this task to acute drug-related impairment has been poor, with effect sizes of 0.2-
0.3 at breath alcohol levels of 0.05 and 0.08 compared to baseline sober states (Cash, 
Peacock, Barrington, Sinnett ,& Bruno, 2015).   
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Manning et al (2017) suggest that the extent of top-down inhibitory control deficits 
and strength of bottom-up drives should be associated with treatment outcomes – 
was this supported?  
Associations between bottom-up drive measures and treatment outcomes  
 
The second hypothesis aimed to test the predictions outlined by the 
theoretical framework, whereby poorer ‘top-down’ inhibitory control and greater 
strength of ‘bottom-up’ drives would be associated with poorer treatment outcomes. 
This was only assessible in the Sativex Trial, and the estimates of variance in 
treatment outcomes associated with bottom up measures were trivial and non-
significant. This is not in line with the proposals of the theoretical framework, and 
are also contrary to previous literature (Fernandez-Serrano et.al.,2012). Bottom-up 
measures have shown to be associated with higher relapse rates (Field & Cox, 2008, 
Sofuoglu et.al., 2013) therefore may also be predictive of poorer treatment outcomes. 
These associations however, were not found to be significant in this study.  
Associations between top-down decision making measures and treatment outcomes 
 
A significant positive correlation was also found between DD and 
SOCRATES measure of ambivalence. This result is also consistent with previous 
literature. Stevens et. al. (2014) found a partial mediation between DD and readiness 
to change. Evidence suggests advantageous decision-making is needed to resolve 
ambivalence towards drug addiction and treatment engagement (LeBerre, Vabret, 
Cauvin, Pinon, Allain, & Pitel, 2012).  
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Associations between top-down inhibitory control measures and treatment outcomes 
 
Measures of top-down inhibitory control (SST) also had trivial and non-
significant independent relationships with early treatment dropout. However, the 
SST has shown to be associated with relapse and treatment drop-out in SUD (Li et. 
al., 2009; Fernandez-Serrano et.al.,2012, Monterosso et. al., 2005). After controlling 
for other key correlates of treatment dropout, SST RT was significantly associated 
with treatment outcomes. Follow up tests revealed when anxiety, and readiness to 
change were removed from the final model, SSRT was non-significance. As SST is a 
time pressured task, it is possible that the correlation between the task and anxiety is 
due the nature of the task itself. However, significant positive correlations were also 
found between dependence and anxiety, depression and readiness to change. These 
results therefore could be attributed to suppressor effects in multiple regression. 
Typically, a suppressor variable is defined as being a variable that is not related to 
the outcome variable, but due to its relationship with another predictor in the model, 
improves the overall model fit (Lancaster, 1999). While it is difficult to identify the 
source of the suppressor effect (Lancaster, 1999), given the statistically significant 
relationships between SSRT and anxiety, it is possible that this is a key contributor to 
the effect. Previous literature has found anxiety to be influencial in SUD populations. 
Comorbidity between SUD and mood disorders are highly prevalent, with studies 
showing significant negative impacts on both symptoms severity (Brorson et al, 
2013) and treatment outcomes (Lubman, 2015; adolescent population).   
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Is anxiety a potential unmeasured variable in cognition-treatment outcome 
literature?   
	
Research into the factors that predict treatment outcome, play an important 
role in generating hypotheses to inform future randomised clinical interventions and 
assess the effectiveness of current best-practice treatments (Byrd & Ho, 2011). Many 
factors have shown to increase the prevalence of relapse in SUD populations, such as 
psychological distress, socio-cultural demographics, treatment motivation and trait 
impulsivity (Brorson, et.al., 2013). Existing research, however, often neglects to 
include a wide range of treatment outcome relevant factors, often due to practical 
constraints, instead focusing solely on the variables directly related to their study 
hypotheses. In the current context, it may be that cognitive task performance and 
anxiety are related, and also that anxiety and outcome are related. As such, if anxiety 
is omitted from a study and only cognitive measures are included, these studies may 
overestimate the contribution of cognitive impairments as predictors of SUD and 
treatment outcomes. In the absence of a control, it is difficult to draw causal 
relationships between variables (Hill, 1965). While the present study controlled for 
some known covariates (e.g. general cognition, impulsivity, psychological distress), 
results were not as strong when compared to previous literature (Monterosso et. al., 
2005, Stevens et.al., 2014, Field et.al., 2009). Studies such as Li et. al., (2009) and 
Monterosso et. al., (2005) controlled for premorbid intelligence and diagnosed 
comorbid mental disorders, however failed to control for other clinically significant 
state factors, such as current psychological distress. Previous significant results may 
therefore be influenced by unmeasured confounding variables and may overstate the 
true extent of shared variance between cognitive impairment and treatment 
outcomes. To support such a view, in an alcohol use population, when controlling for 
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other factors contributing to treatment outcomes (age, legal obligation, depressive 
symptoms and baseline alcohol use) anxiety sensitivity significantly was a significant 
predictor of early treatment dropout (Lejuez et.al., 2008).  
There have been multiple studies among cannabis consumers demonstrating 
substantial correlations between anxiety sensitivity and extent of dependence and 
between anxiety sensitivity and treatment outcomes (Keough, Hendershot, Wardell, 
& Babdy, 2018; Zvolensky, et.al., 2018; Norberg, Olivier, Schmidt, & Zvolensky, 
2014). Zvolesky et.al. (2018) found when controlling for all other factors tested 
(gender, years of cannabis use, negative affectivity, nicotine and alcohol use) anxiety 
sensitivity significantly explained variance in cannabis use problems (3%), perceived 
barriers to quitting (7%) and fear of quitting (11%). A study conducted by Keough 
et.al. (2018) found significant moderate correlations between impulsivity (negative 
urgency) and both anxiety sensitivity (r = .59, p <.01) and cannabis problems (r =.38, 
p <.01). Norberg, Olivier, Schmidt, & Zvolensky (2014) found evidence to suggest 
anxiety could be a mediating variable between between cannabis severity and early 
drop-out, with results showing a partial indirect effect. Similarly, a systematic review 
of a  large number of correlates of treatment drop-out, identified medium to large 
effect sizes between early drop-out and anxiety (Brorson et. al., 2013). Given these 
shared relationships between cognition, anxiety and outcome, longitudinal rather 
than cross-sectional studies are needed to determine whether cognition or anxiety is 
the key driver of the relationship with outcome (Hill, 1965).    
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Limitations of study 
	
Drug-based research does not have the ability to utilise a control/no treatment 
group or randomise conditions. Therefore, it is difficult to draw strong inferences 
about causality (Hill, 1965). Preexisting differences between participants may 
predispose them to particular patterns of drug use seen in the study. Research 
suggests SUD is often a self-medicating mechanism for individuals suffering 
depression and/or anxiety (Parks & Kennedy, 2004). Many participants scored high 
on psychological distress measures, which as previously discussed may have 
contributed to results of the study. 
 Self-selected groups also include inherent bias and therefore fails to provide 
a representation of the general SUD population (Curran, 2000). Participants in CTx 
showed a DSM-IV moderate to severe SUD symptom count. While inclusion criteria 
for Sativex trial, required participants to have previous unsuccessful treatment 
attempts. These samples are therefore representative of severe SUD and not the 
general drug using population. Sativex trial used data from the placebo group of a 
Randomised Control drug Trial (RCT). Meta-analysis shows RCT drop-out to be on 
average higher than the general clinical population (Kemmler, Hummer, and 
Widschwendter, 2005). On average general clinical drop out at 4 weeks is 55% 
(AIHW, 2017). While on average drop-out in placebo arm RCT is 60.2 % overall 
(Kemmler, Hummer, and Widschwendter, 2005). Results therefore may not be easily 
generalisable in a clinical setting Further research in the general clinical population 
with a wider spread of participants across levels of SUD severity would be ideal.  
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Results from self-reported measures of previous drug use are reliant on the 
honesty of participant and thus subject to individual bias. The present study used a 
TLFB to measure baseline drug use and both AUDADIS-5 (CTx) and CPQ (Sativex 
trial). Using this method however do fail to quantify the purity and content of illicit 
substances consumed. The TLFB collects data as to quantity of substance consumed 
but not how strong/pure the substance is. This may have added variance to results. 
The study also focused on the participant’s main substance and did not account for 
potential poly-substance use. This may also have added variance to results found  It 
is therefore expected that self-report measures of previous drug use and severity of 
dependence in this study are to be imprecise to some extent. However, Harrison, 
Martin, Enev and Harrington (2007) found agreement between hair and urine 
samples and self-report measures of previous drug use on a range of illicit substances 
to be 91.5%. These results were similar (between 71% and 95%) in a systematic 
review conducted by Darke (1998).  
Studies have consistently found impairments in cognitive functioning across 
all drug type (Manning et. al., 2017). Sativex trial data consist of a cannabis use 
population. CTx sample consisted of a majority alcohol population. Greater 
generalisability in drug type would enhance future research. Difficultly in 
recruitment for the originally proposed study lead to a small sample size. 
Underpowered studies can yield false positive or null findings (Button et al., 2013). 
Results reported from CTx study are therefore more susceptible to type one and two 
errors. Sativex trail data however did met power calculations for reliable 
identification of a statistically significant effect.   
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Brorson et.al. (2013) identified mixed results in studies investigating the 
association between motivation and treatment drop out. Two studies found no 
significant relationship between motivation and dropping out, whereas one study 
reported a positive association. According to the transtheoretical model of stages of 
change, only 20% of those presenting for treatment are ready to take action and 
modify their behaviour, experiences, and/or environment to overcome their problems 
(Norcross, Krebs,& Porchaska, 2011). As the studies recruitment strategy was at 
arm’s length and required self-selecting, the sample of participants may have been 
more intrinsically motivated at baseline to stay the course of treatment, therefore 
amplifying the significant results found for treatment readiness in this study.  Despite 
the strength of this study in controlling for a number of potential covariates, the 
study was not able to measure all known factors contributing to treatment outcomes.  
This study assessed readiness to change and found significant associations between 
readiness and both cognitive mechanisms and dependence. The study however did 
not include other potential treatment factors such as treatment setting, duration, 
satisfaction or therapeutic alliance. Fewer studies have explored the relationships 
between these factors and treatment outcome (Brorson et.al., 2013). 
Implications and directions for future research 
	
There has been much research into individual factors contribute to treatment 
outcomes in out-patient talk-based therapy (Turner et.al., 2009; Stevens et.al., 2015), 
but lack an overarching theoretical framework. Engagement in treatment programs is 
necessary for successful rehabilitation, with a minimum of three months 
recommended (Katz, et. al. 2004). However, more than half (55%) of treatment 
seekers drop-out after less than a month (AIHW, 2017). Researchers argue that 
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cognitive deficits may interfere with treatment seekers ability to engage in or benefit 
from these treatments (Lyvers, 2000) with severity of SUD shown to increase in 
cases where treatment is unsuccessful or underutilized (Baconi et al., 2015).  The 
study shows some evidence in support of the theoretical framework proposed by 
Manning et.al.(2017). In understanding the theoretical framework underpinning 
cognitive impairments and their relationship to treatment outcomes, interventions can 
be created to address these impairments and to help treatment seekers engage more 
effectively in treatment. This framework merits further critical investigation and 
expansion to consider a range of other factors contributing to outcome, and also the 
therapeutic processes that may be affected by cognitive problems.  
The study findings also highlight anxiety as a possible unmeasured variable 
in previous cognition-outcome literature.  There is much evidence for psychological 
distress as a strong predictor of treatment outcomes, however many previous studies 
fail to control for the variable when assessing associations between cognitive 
impairments and treatment outcomes. The main advantage of this study is its 
comprehensive covariate measures. To achieve better validity and re-test reliability 
when measuring previous ability of cognitive impairment, future studies should 
control for known factors of poor treatment outcomes (in particular anxiety and 
readiness to change). To build upon the current study, it would be interesting to 
explore the relationship between anxiety, cognitive impairments and treatment 
outcomes, as the study and previous literature indicate anxiety to be a possible 
mediatory variable .   
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 Systematic review found traditional (12 steps program) approaches to 
therapy were found be less effective in comorbid anxiety and SUD populations when 
compared to pure SUD populations (Smith & Book, 2010). There are a number of 
interventions available for anxiety and anxiety sensitivity, for both top-down 
inhibitory control, and bottom-up drives. CBT was found most effective by Smith 
and Book (2010). Other common psychosocial therapies include MET and 
psychodynamic therapy/interpersonal therapy (Bandelow, Michaelis, & Wedkind, 
2017). However, there is a lack of understating in how these interventions relate to 
outcomes in SUD populations. Therefore, it is difficult to assess which to use to 
support better clinical outcomes in treatment. As resources are limited, more research 
is needed in assessing outcomes of treatment in clinical populations, so that when 
evidence based clinical interventions are created, there is greater validity and thus 
therapeutic value.   
Few studies have explored the relationships between DD and early-dropout 
rates, with much focus on DD as a predictor of relapse (Stevens el.al., 2014). Out-
patient therapy is largely based around goal setting, thus, the ability to see and 
choose long term progress rather than the immediate gratification is necessary for 
therapy success. Correlations between top-down DD and dependence was significant 
treatment. However, limited time frame of study and low attrition rate at one-month 
follow provided insufficient data to measures treatment outcome in CTx. Further 
research exploring the relationship between DD and treatment outcomes would 
bridge the gap in previous literature.   
54	
	
	
	
Summary and Conclusions 
In summary, the aim of the current study was to test the theoretical 
framework proposed by Manning et al (2017) that suggests that severity of 
dependence is associated with impairments in top-down inhibitory control and 
increases in bottom-up substance related drives, and that these cognitive measures 
are, in turn, related to treatment outcomes.  
The study findings showed mixed evidence to support the theory 
underpinning the framework. Response inhibition (SST, top-down measure) and 
attentional bias (DP, bottom-up measure) were not significantly associated with 
severity of SUD. However, decision making (DD, top-down measure) and 
compulsivity (MCQ, bottom-up measure) to be significantly associated with severity 
of SUD in the two studies reported here.  
The study findings did not support the predictions made by the framework. 
Greater bottom-up drives (MCQ compulsivity) and poorer top-down inhibitory 
control (SST) were not predictive of poorer treatment outcomes. Previous studies 
analyzing the relation between cognition and treatment outcomes failed to control for 
psychological distress and readiness to change. After controlling for other key 
correlates of treatment dropout (anxiety, and readiness to change), top-down (SST) 
measure was significantly associated with treatment outcomes.  
In conclusion, the findings of the current study show some support for the 
theoretical framework proposed by Manning et al (2017). The findings highlight the 
multifaceted way in which people can remain stuck in substance use disorder, and 
requires further research attention in order to identify cognitive interventions that 
will be the most complementary to existing treatments.   
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Appendix  
A. Recruitment Poster 
Have	you	just	started	treatment	for	problems	
with	alcohol	or	drug	use?	We	need	your	
brainpower!	
University	researchers	are	studying	how	your	thinking	(memory,	
reaction	time,	decision	making)	relates	to	progress	in	treatment.		
This	will	help	us	work	out	the	types	of	thinking	skills	that	are	most	
closely	related	to	good	treatment	outcomes.	It	will	also	help	select	‘brain	
training’	packages	that	might	help	people	get	better	results	from	treatment	for	
their	substance	use.		
If	you’re	interested,	there’s	a	60-90	minute	session	at	the	University,	where	
you	will	complete	some	surveys	and	measures	of	your	thinking.	We’ll	provide	
you	$40	for	your	time	and	expenses.		
We’d	also	like	to	check	in	with	you	a	month	later	to	see	how	you’re	doing.		
Three	months	later,	we’d	like	to	get	you	back	to	the	university	to	do	these	measures	again	
(we’ll	provide	another	$40	for	this	bit).	With	your	approval	we’d	also	like	to	ask	your	
counsellor	about	your	improvement	over	treatment.		
	
	
 
This study has UTAS Ethics approval #H0017170 
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Appendix  
B. Participant Information Sheet 
Cognition and Drug Treatment Outcomes 
Invitation 
This is an independent study conducted by Associate Professor Raimondo Bruno, in 
the School of Medicine (Psychology) at the University of Tasmania.  
What is the purpose of this study? 
We are seeking to better understand how your thinking relates to progress in 
treatment for problems with substance use.  
By ‘thinking’ we mean a range of different things, such as concentration, memory, 
attention, the ability to put the breaks on your responses, and your decision making 
about short and long term consequences. There has been a number of studies that 
have shown that these sorts of skills are related to how well people do in their chosen 
‘talk based’ treatment for substance use problems (like counselling). There is also a 
number of training programs that are in development to help people improve on 
these aspects of thinking.  
What we’re aiming to do is to work out which are the best types of thinking skills to 
measure that are most closely associated with how well people go in treatment. We 
can then target these with particular brain training programs to see if they will help 
improve outcomes for people seeking treatment for problems with substance use.  
Why have I been invited to participate? 
We’re inviting anyone who has just started treatment in ‘talk-based’ therapies (like 
counselling and psychology) for a problem with any substance they use (except for 
tobacco).  
We don’t want to get in the way of your treatment, though. It is important that you 
know that this study is completely independent from whatever service you are 
attending. We have invited people at all drug treatment services in Hobart to take 
part in this study. If you don’t want to take part in this study, that is OK, and it is not 
going to have any impact on the way you are treated by this service. If you start 
taking part in this study, and decide that you don’t want to continue, that’s not going 
to have any impact on how your treatment service will treat you either.  
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What will I be asked to do? 
There are a number of parts to this study.  
After making sure that you are eligible to take part, there is a 60-90 minute research 
session at the University of Tasmania. Here we would ask you questions about your 
substance use, such as how often you have used in the last 4 weeks, and any 
problems you have been experiencing from the substance. You’ll be asked about any 
feelings of craving for the substance you have problems with. There are also some 
questions about where you’re at in terms of wanting to change your substance use. 
These will likely cover similar types of questions that your counsellor or 
psychologist asked in your first assessment session. There will be some questions 
about your mood and your personality style. For all of these, it is really important to 
know that if you’re not comfortable about talking about these things, it’s OK just to 
tell us that you don’t want to talk about it, or to say you don’t want to answer a 
particular question. We won’t give you a hard time about it, and whatever you decide 
to do isn’t going to impact on the way that your drug treatment provider treats you.  
In this same session, there are a bundle of thinking tasks. These might ask you to 
pronounce some unusual words out loud (like ‘yacht’), to pick the direction of an 
arrow on screen as quickly as possible, or say the colour that words are written in. 
There’s also some tasks where you have to remember to hold back hitting a key on a 
keyboard every now and then after you have been responding as quickly as you can 
to targets on the screen. There’s some tests of memory where you have to remember 
a number that has been shown to you. Lastly, there are some tests of the way you 
make decisions. One uses a virtual bunch of decks of cards which give you different 
monetary outcomes and you’ll need to pick from each deck to try to get the best 
outcome at the end. The other asks you to make hypothetical decisions between 
whether you would prefer to have a small amount of money now or a larger amount 
of money later, over different amounts and timeframes.  
This sounds like a lot but each of these things only takes 2-5 minutes, and you can 
take regular breaks (we’ll remind you about this option).  
The other bits of the study are:  
- We’d like to ask if it is ok to check in with you by phone or email four weeks 
after you start treatment to see how you are going 
- We’d like to ask if it is OK to check with your therapist / counsellor 12 weeks 
after you start treatment to see how many sessions you attend, and their 
opinion of your improvement over that time 
- We’d like to invite you to come back to the University to repeat most of the 
things you did in that first research session, and also ask your opinion of your 
improvement over time.  
75	
	
	
	
It is important to know that it’s up to you whether you want to do any of these bits of 
the study, and if you are only ok with some bits and not others, that’s ok, you can 
still take part in the bits of the study that you are comfortable with. 
Are there any possible benefits from participation in this study? 
The main benefit from taking part in this study is making a contribution to helping 
understand how to improve outcomes for drug treatment.  
We appreciate your time and inconvenience in contributing to research, and we are 
able to provide reimbursement of $40 for each of the sessions at the university ($80 
in total).  
Are there any possible risks from participation in this study? 
There are a number of risks involved in taking part in this study, but they are quite 
similar to the risks involved in seeking treatment for your problem substance use.  
Firstly, there are some questions about your mood. These might cause you to think 
about how your mental health is. If they cause you distress, this might be something 
you can discuss with your current counsellor / therapist. Or, if you need to discuss 
something straight away, there are a number of options available 24 hours a day, 7 
days a week, including Lifeline (13 11 14), beyond blue (1300 22 4636) or 
counselling online (https://www.counsellingonline.org.au/) 
Secondly, we are acutely aware of the degree of unfortunate social stigma that is 
associated with substance use. We have a number of steps in place to protect your 
confidentiality (more on this below). The other aspect of this is that there are legal 
issues associated with drug use. In this study, we have a number of questions that ask 
about your use of substances, and in some cases this may include illegal substances.  
We will generally not disclose to anyone information about your use of substances 
without your consent. However, there may be some circumstances where we have to 
do so for legal reasons. In that case, the information could potentially be used against 
you in legal proceedings or otherwise (for example, information about drug use 
could be considered relevant in a criminal investigation or in relation to the Family 
Court). To our knowledge, researchers in this institution have not been required by 
law to provide information. Certainly, the investigators in this study have conducted 
interviews about substance use for the past 15 years with more than 3000 people and 
have never been required to provide any information. If, however, we were ever 
required to do so, we would do our best to notify you before disclosing it.  
We have a number of protections in place to reduce this risk. Firstly, the consent 
forms with identifying information (such as your contact details) are kept separately 
from all other information from this study (such as the questions about your 
substance use). They are stored securely at the University. All information from the 
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study is stored only with a study ID (e.g. CTX777). As soon as you complete the 
study, any link between your identifying information and study ID is securely 
destroyed, making it very difficult for an individual person to be identified by their 
data.  
What if I change my mind during or after the study? 
As noted above, it is completely fine for you to decide not to answer any questions 
that you’re not comfortable with. That won’t affect your relationship with the 
university and it won’t affect your treatment by your counsellor. The same applies if 
you start the study and then decide that it is not for you. You don’t need to explain 
why.  
If you decide that you don’t want to be part of the study, and you let us know before 
the end of your participation in the study, we’ll be able to work out which data is 
yours and we can delete all records and securely destroy any consent forms. If you 
let us know after you have finished all the parts of the study, we won’t be able to 
remove your data because we would have destroyed the links between your 
identifying information and the study ID.  
What will happen to the information when this study is over? 
Identifying information will be destroyed as soon as any individual participant 
completes their part of the study. All the information about performance on the 
different tasks and the like are stored only using study ID. This will be stored in an 
electronic database, on secured University of Tasmania servers, and password 
protected. Hard copies (of your consent form using a pseudonym that doesn’t link 
with a study ID) are stored in locked filing cabinets in University of Tasmania 
storage archives. Both electronic and hard copy data will be destroyed five years 
after the first publication from this study.  
A reminder: any information obtained for the purpose of this study that can identify 
you will be destroyed as soon as you have completed your part in the study or 
withdrawn your consent. All information, regardless of whether it is identifying or 
not, will be treated as confidential and always securely stored. It would only be 
disclosed with your permission or in compliance with the law.  
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How will the results of the study be published? 
Study findings will be presented in formal publications and in conference 
presentations to people in the substance use field. Only group level analyses will be 
reported, so there is no way that a particular individual could be identified in any 
publication. The results will be available on the university of Tasmania publications 
repository, WARP (https://rmdb.research.utas.edu.au/public/rmdb/q/warp_home) or 
specifically here: 
https://rmdb.research.utas.edu.au/public/rmdb/q/indiv_detail_warp_trans/3812#resea
rch-tab-5. You can also contact Raimondo Bruno directly here: 
Raimondo.Bruno@utas.edu.au 
What if I have questions about this study? 
If you have questions about the study, you can contact Raimondo Bruno at 03 6226 
2240 or Raimondo.Bruno@utas.edu.au.  
This study has been approved by the Tasmanian Health and Medical Human 
Research Ethics Committee. If you have concerns or complaints about the conduct of 
this study, please contact the Executive Officer of the HREC (Tasmania) Network on 
+61 3 6226 6254 or email human.ethics@utas.edu.au. The Executive Officer is the 
person nominated to receive complaints from research participants. Please quote 
ethics reference number H0017170. 
Thank you for your interest in the study, and your time in reading this 
information sheet. This is for you to keep. If you want to take part in this study, 
there are three consent forms for you to complete. These will be stored 
separately from study documents.   
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Appendix  
C. Ethics Approval Letter 
Dear AssocProf Bruno, 
Reference number: H0017170 
Title: COGNITION AND DRUG TREATMENT OUTCOMES  A PILOT STUDY 
We are pleased to advise that this study has been approved by the Tasmanian Human 
Research Ethics Committee and a signed approval letter will be emailed to you provided we 
have received the signed copy of the final approved application.  If you have not already 
done so, please submit your signed application to human.ethics@utas.edu.au. 
Please be advised that the Chief Investigator cannot also sign in place of the Head of 
School/Department. Please note that if the Head of School/Department is listed as one of the 
investigators, this statement must be signed by an appropriate person, such as the Dean. 
This approval constitutes ethical clearance by the Health and Medical HREC. The decision 
and authority to commence the associated research may be dependent on factors beyond the 
remit of the ethics review process. For example, your research may need ethics clearance 
from other organisations or review by your research governance coordinator or Head of 
Department. It is your responsibility to find out if the approval of other bodies or authorities 
are required. It is recommended that the proposed research should not commence until you 
have satisfied these requirements. 
 
In accordance with the National Statement on Ethical Conduct in Human Research, it is the 
responsibility of institutions and researchers to be aware of both general and specific legal 
requirements, wherever relevant. If researchers are uncertain they should seek legal advice to 
confirm that their proposed research is in compliant with the relevant laws. University of 
Tasmania researchers may seek legal advice from Legal Services at the University.” 
Please contact us if you require further information. 
With kind regards 
Heather Vail 
Executive Officer | Health and Medical Human Research Ethics Committee 
Research Integrity and Ethics Unit | Research Division 
University of Tasmania 
Heather.vail@utas.edu.au 
+61 3 6226 5520 
CRICOS 00586  
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Appendix  
D. Cognition and Drug Treatment Outcomes: Screening 
What is this study about?  
We are seeking to better understand how your thinking relates to progress in 
treatment for problems with substance use.  
By 'thinking' we mean a range of different things, such as concentration, 
memory, attention, the ability to put the breaks on your responses, and your 
decision making about short and long term consequences. There has been a 
number of studies that have shown that these sorts of skills are related to how 
well people do in their chosen 'talk based' treatment for substance use 
problems (like counselling). There is also a number of training programs that 
are in development to help people improve on these aspects of thinking.  
What we're aiming to do is to work out which are the best types of thinking 
skills to measure that are most closely associated with how well people go in 
treatment. We can then target these with particular brain training programs to 
see if they will help improve outcomes for people seeking treatment for 
problems with substance use.  
Who are we inviting to participate?  
We're inviting anyone who has just started treatment in 'talk-based' therapies 
(like counselling and psychology) for a problem with any substance they use 
(except for tobacco).  
What does taking part involve?  
After making sure that you are eligible to take part, there is a 60-90 minute 
research session at the University of Tasmania. In this session, we ask about 
your substance use, your treatment, and ask you to complete a bundle of 
thinking tasks. One month later, we'd like to give you a call to check in to see 
how you are going with your treatment. Three months later we'd like to invite 
you back to complete most of the things you did in the first session, to see how 
things have changed. You will be reimbursed $40 for each session you attend.  
For more details about the study and what it involves, please click here. If you 
have any further questions about the study, email us at ctxstudy@gmail.com.  
Are you over 18 years of age ?  
o Yes   
o No  
What is your age in years? __________________________________  
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What is your sex?  
o Female  
o Male  
o Other  
What is your main language ?  
o English  
o Other  
What is your main language?__________________________________
Have you started treatment (counselling, psychology, any 'talk therapy') for a 
problem with substance?  
o Yes 
o No  
When did (or will) you start this treatment ? (please specify date - an estimate 
is fine) __________________________________
What is the name of the service that you are attending for treatment? 
__________________________________  
How many sessions does your treatment provider offer per week? (leave blank 
if you don't know) __________________________________
How many sessions have you attended so 
far?__________________________________  
Have you engaged in treatment before?  
o Yes  
o No  
Has your treatment been required (mandated) by the court?  
o Yes  
o No  
What is the main substance you are concerned about?  
alcoholcannabis methamphetamine opioidsother  
Specify the other drug type __________________________________
Are you taking medications for your substance use problem ?  
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o Yes  
o No  
What is the name of the medication? 
__________________________________  
Are you currently in inpatient (hospitalised) withdrawal?  
o Yes 
o No  
Are you in residential treatment program for your substance use problem? 
(e.g. admitted to a private hospital or a rehabilitation service?)  
o Yes 
o No  
Thank you for answering the screening questionnaire, we appreciate 
your assistance. If you are eligible to participate, the researchers 
will be in contact with you as quickly as possible. All of your 
contact details will be kept confidential and are securely stored. 
You can use a fake name if you prefer!  
Please email us at ctxstudy@gmail.com if you have any queries.  
What is your e-mail address? This is so we can contact you. 
__________________________________
What is the phone number you are most easily reached on? 
__________________________________  
Please indicate which days would best suit for us to come to the University for 
an 60-90 minute interview (if you are eligible)  
o Monday 
o Tuesday  
o Wednesday  
o Thursday  
o Friday  
o Specify time  
o 9am-12pm  
o 12pm-3pm 
o 3pm-6pm  
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Appendix  
E. Attentional Bias Dot Probe Stimuli 
Alcohol	stimuli	(*a	stimuli)	and	matches	(*b	stimuli)	and	filler	stimuli	
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Amphetamine	stimuli	(*a	stimuli)	and	matches	(*b	stimuli)	and	filler	stimuli	
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Cannabis	stimuli	(*a	stimuli)	and	matches	(*b	stimuli)	and	filler	stimuli	
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Opioid	stimuli	(*a	stimuli)	and	matches	(*b	stimuli)	and	filler	stimuli	
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Appendix  
E. Experiment 1 CTx Data 
Table 1 Correlations all variables measured in Experiment 1 CTx for both original data and data with outliers removed 
Variables  DDRTms SSRTms DDlog k Dependence WTAR MoCa k10 Recognition Ambivalence Taking Steps I7 
  r p r p r p r p r p r p r p r p r p r p r p 
Bottom-Up 
(DPRTms) 
o 
 
- - .575 .177 .118 .801 -.096 .839 
-
.060 .911 .377 .461 
-
.289 .579 -.376 .462 -.466 .388 
-
.358 .486 .454 .366 
d - - .755 .177 -.246 .638 
-
.096 .838 
-
.060 .911 .377 .461 
-
.289 .579 -.376 .462 -.436 .388 
-
.358 .486 .454 .366 
Top-Down 
(SSRTms) 
o 
 
  - - .406 .366 .287 .532 .312 .547 .664 .150 -.303 .560 -.263 .614 -.047 .930 .050 .926 
-
.198 .707 
d   - - -.044 .934 .287 .532 .312 .547 .664 .150 
-
.303 .560 -.263 .614 -.047 .930 .050 .926 
-
.198 .707 
Top-Down 
(DD log k) 
o 
 
    - - .516 .236 -.350 .496 .307 .554 .560 .361 .376 .462 .169 .748 
-
210 .689 .205 .697 
d     - - .813 .049* -.729 .160 
-
.614 .271 .844 .072 .807 .099 .900 .037* .668 .218 .135 .829 
Dependence 
(DSM 
symptom 
count) 
o       - - -.653 .161 
-
.497 .316 .842 .036* .893 .017* .746 .088 .410 .420 .107 .840 
d       - - -.653 .160 
-
.497 .316 .842 .036* .893* .017* .746 .088 .410 .420 .107 .840 
WTAR 
o         - - .651 .161 .806 .53 -645 .167 -.352 .494 -.008 .998 
-
.748 .087 
d         - - .651 .161 -.806 .053 -.645 .167 -.352 .494 
-
.008 .988 
-
.748 .087 
MoCa o           - - -.622 .187 -.692 .128 -.452 .368 
-
.284 .585 
-
.282 .588 
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d           - - -.622 .187 -.692 .128 -.452 .368 
-
.282 .585 
-
.282 .588 
k10 
o             - - .942 .005** .532 .225 .124 .814 .322 .533 
d             - - .942 .005** .582 .225 .124 .814 .322 .588 
SOCRATES 
recognition 
o               - - .712 112 .321 .535 .062 .907 
d               - - .712 .112 .321 .535 .062 .907 
SOCRATES 
ambivalence 
o                 - - .872 .024* -.337 .513 
d                   .872 .024* -.337 .513 
SOCRATES 
taking steps 
o                   - - -.541 .268 
d                     .541 .268 
Impulsivity 
(I7) 
o                     - - 
d                     - - 
Note:	o=	original	data,	d=	data	without	delayed	discounting	outliers,	*	p	<	.05,	**p	<.01 
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Appendix		
F.	Experiment 2 Data 
Table 1 Correlations all variables measured in Experiment 2 for both original data and data with participant with low SSRT scores 
removed	
Variables  1 2 3 4 5 6 7 8 9 10 
  r p r p r p r p r p r p r p r p r p r p 
1.Bottom-Up 
(Compulsivity) 
o 
 
- - -.200 .110 .314 .010** .115 .353 
-
.043 .733 .311 .010* .178 .150 .358 .003** -.125 .312 .071 .570 
s - - -.217 .078 .314 .010** .115 .353 
-
.043 .733 .311 .010* .178 .150 .358** .003 -.125 .312 .071 .570 
2. Top-Down 
(SSRTms) 
o 
 
  - - -.188 .134 
-
.066 .600 .157 .218 
-
.319 .010** 
-
216 .084 -.265 .033 -.153 .224 
-
.105 .405 
s -.217 .078 - - 
-
.186 .133 
-
.074 .554 .115 .360 
-
.327 .007** 
-
.198 .109 -.281 .021* -.140 .259 
-
.076 .541 
3. Dependence  
 
o     - - .014 .910 .017 .896 .556 <.001*** .662 <.001*** .473 <.001*** -.094 .450 
-
.028 .823 
s     - - .014 .910 .017 .896 .556 <.001*** .662 <.001** .473 <.001*** -.094 .450 -.028 .823 
4.Baseline 
Substance use 
o .115 .353 -.074 .554 .014 .910 - - 
-
.196 .117 .040 .746 .002 .987 .088 .479 -.221 .073 
-
.152 .218 
s .115 .358 -.074 .554 .014 .910 - - 
-
.196 .117 .040 .746 .002 .987 .088 .479 -.221 .073 
-
.152 .218 
5.WTAR  
o         - - .023 .854 -.105 .405 .167 .185 -.200 .109 .048 .707 
s         - - .023 .854 -.105 .405 .167 .185 -.200 .109 .048 .707 
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6. Anxiety  
o           - - .581 <.001** .443 <.001** -.078 .528 -.114 .356 
s           - - .581 <.001** .443 <.001** -.078 .528 -.114 .356 
7. Depression  
o     .662 <.001***   -.105 .405 .581 <.001*** - - .334 .006** -.024 .847 .007 .953 
s     .662 <.001***   -.105 .405 .581 <.001*** - - .334 .006** -.024 .847 .007 .953 
8. Readiness to 
change  
o           .443 <.001***   - - -.200 .104 -.081 .514 
s           .443 <.001***   - - -.200 .104 -.081 .514 
9. Still in Tx 
Week 4 
o                 - - .421 <.001*** 
d                 - - .421 <.001*** 
10. Still in Tx 
Week 12 
o                   - - 
s                   - - 
                      
Note: o=	original	data,	s=	data	without	SSRT	outliers *p < .05, **p < .01 
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Table 2  
Mean, Standard deviation and Effect sizes for participants still in treatment at week 4 and 
12.      
Measure Retained Dropped out t ( p) BF01 d 
M SD N M SD N 
Top-down 
inhibition 
(SSRT, ms) 
Week 
4 
500 119 53 547 122 12 1.23(.224) .563 .393 
Week 
12 
494 104 29 520 132 36 .84(.405) .344 .209 
 
Table 3 
Hierarchical linear regression of associations between dependence and cognition  
	 Top-Down		
(SSRTms)	
Variable	 t	 p	 R2	
Model	1	 	 	 .04	
Dependence	 -1.62	 .111	 	
Model	2	 	 	 .07	
Dependence	 -1.79	 .08	 	
WTAR	 1.47	 .15	 	
Model	3	 	 	 .15	
Dependence	 -0.19	 0.85	 	
WTAR	 1.60	 0.11	 	
Depression	 -0.30	 0.77	 	
Anxiety	 -2.01	 0.05	 	
Note: * Significant result, p < .01.   
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Table  4 
Hierarchical logistic regression of associations between cognition and treatment outcomes  
Variable	 Week	4	 	 Week	12	
Odds	
ratio	
95%	CI	 p	 R2	 	 Odds	
ratio	
95%	CI	 P	 R2	
Model	1	 	 	 	 .038	 	 	 	 	 .004	
Top-down	
(SSRT	ms)	
1.00	 (0.99-
1.00)	
.252	 	 	 0.99	 (0.99-
1.00)	
.652	 	
Model	2	 	 	 	 092	 	 	 	 	 .012	
Top-down	
(SSRT	ms)	
1.00	 (0.99-
1.01)	
.165	 	 	 0.99	 (0.99-
1.00)	
.733	 	
Bottom-up	
(Compulsivity)	
1.11	 (0.96-
1.28)	
.154	 	 	 1.03	 (0.93-
1.15)	
.571	 	
Model	3	 	 	 	 .133	 	 	 	 	 .013	
Top-down	
(SSRT	ms)	
1.00	 (0.99-
1.01)	
.266	 	 	 0.99	 (0.99-
1.00)	
.703	 	
Bottom-up	
(Compulsivity)	
1.12	 (0.97-
1.29)	
.120	 	 	 1.03	 (0.92-
1.15)	
.563	 	
WTAR	 1.04	 (0.97-
1.12)	
.228	 	 	 1.00	 (0.96-
1.05)	
.823	 	
Model	4	 	 	 	 .159	 	 	 	 	 .051	
Top-down	
(SSRT	ms)	
1.00	 (0.99-
1.01	
.184	 	 	 0.99	 (0.99-
1.00)	
.571	 	
Bottom-up	
(Compulsivity)	
1.11	 (.95-
1.18)	
.180	 	 	 1.04	 (0.93-
1.17)	
.447	 	
WTAR	 1.04	 0.97-
1.11)	
.284	 	 	 1.01	 (0.9.6-
1.06)	
.708	 	
Anxiety	 1.13	 (0.89-
1.45)	
.306	 	 	 1.05	 (-.75-
1.07)	
.226	 	
Depression	 0.97	 (0.86-
1.09)	
.612	 	 	 1.05	 (0.96-
1.15)	
.303	 	
Model	5	 	 	 	 .387	 	 	 	 	 .087	
Top-down	
(SSRT	ms)	
1.01	 (1.00-
1.02)	
046	 	 	 0.99	 (0.99-
1.00)	
.459	 	
Bottom-up	
(Compulsivity)	
1.00	 (0.84-
1.20)	
.972	 	 	 1.07	 (0.94-
1.21)	
.286	 	
WTAR	 1.03	 (0.96-
1.11	
.403	 	 	 1.01	 (0.96-
1.06)	
.630	 	
Anxiety	 1.17	 (0.89-
1.53)	
.261	 	 	 0.91	 (9.75-
1.09	
.307	 	
Depression	 0.98	 (0.84-
1.15	
.819	 	 	 1.06	 (0.95-
1.17)	
.314	 	
Readiness	to	
change	
1.06	 (0.97-
1.14)	
.178	 	 	 0.98	 (0.95-
1.03)	
.510	 	
Baseline	
cannabis	use	
2.02	 (-0.87-
4.70)	
.102	 	 	 0.94	 (0.84-
1.06)	
.326	 	
Dependence	 1.00	 (0.97-
1.04)	
.777	 	 	 0.99	 (0.98-
1.02)	
.835	 	
Note: * Significant result, p = .05.  
